Population pharmacokinetics of meropenem during continuous infusion in surgical ICU patients

Journal of Clinical Pharmacology

Volumn 56, Issue 3, 2016, Pages 307-315

  Kees, Martin G ^a   Minichmayr, Iris K ^b   Moritz, Stefan ^c   Beck, Stefanie ^d   Wicha, Sebastian G ^b   Kees, Frieder ^e   Kloft, Charlotte ^b   Steinke, Thomas ^c  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b FREIE UNIVERSITÄT BERLIN   (Germany)

^c MARTIN LUTHER UNIVERSITÄT HALLE WITTENBERG   (Germany)

^d UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^e UNIVERSITY OF REGENSBURG   (Germany)

Author keywords

critical care; cystatin C; nosocomial infection; pharmacodynamics; renal function

Indexed keywords

CREATININE; CYSTATIN C; MEROPENEM; ANTIINFECTIVE AGENT; THIENAMYCIN DERIVATIVE;

ABDOMINAL INFECTION; ADULT; AGED; APACHE; ARTICLE; CLINICAL ARTICLE; CONCENTRATION AT STEADY-STATE; CONTINUOUS INFUSION; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DRUG BLOOD LEVEL; FEMALE; HOSPITAL INFECTION; HUMAN; INTENSIVE CARE UNIT; KIDNEY FUNCTION; MALE; MULTIPLE TRAUMA; PNEUMONIA; PROSPECTIVE STUDY; SUBARACHNOID HEMORRHAGE; SURGICAL PATIENT; VERY ELDERLY; WOUND INFECTION; BIOLOGICAL MODEL; BLOOD; CLINICAL TRIAL; CRITICAL ILLNESS; GENERAL SURGERY; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY FUNCTION TEST; MIDDLE AGED; MULTICENTER STUDY; URINE; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; CREATININE; CRITICAL ILLNESS; CYSTATIN C; GENERAL SURGERY; HUMANS; INFUSIONS, INTRAVENOUS; KIDNEY FUNCTION TESTS; MIDDLE AGED; MODELS, BIOLOGICAL; PROSPECTIVE STUDIES; THIENAMYCINS; YOUNG ADULT;

EID: 84958115367     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1002/jcph.600     Document Type: Article

References (38)

1. Roberts JA, Abdul-Aziz MH, Lipman J, et al., Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions. Lancet Infect Dis. 2014; 14 (6): 498-509.
2. Craig WA., Basic pharmacodynamics of antibacterials with clinical applications to the use of β-lactams, glycopeptides, and linezolid. Infect Dis Clin North Am. 2003; 17 (3): 479-501. doi: 10.1016/S0891-5520(03)00065-5.
3. Gonçalves-Pereira J, Põvoa P., Antibiotics in critically ill patients: a systematic review of the pharmacokinetics of β-lactams. Crit Care. 2011; 15 (5): R206. doi: 10.1186/cc10441.
4. Carlier M, Carrette S, Roberts JA, et al., Meropenem and piperacillin/tazobactam prescribing in critically ill patients: does augmented renal clearance affect pharmacokinetic/pharmacodynamic target attainment when extended infusions are used? Crit Care. 2013; 17 (3): R84.
5. Roberts JA, Paul SK, Akova M, et al., DALI: defining antibiotic levels in intensive care unit patients: are current β-lactam antibiotic doses sufficient for critically ill patients? Clin Infect Dis Off Publ Infect Dis Soc Am. 2014; 58 (8): 1072-1083. doi: 10.1093/cid/ciu027.
6. Patel BM, Paratz J, See NC, et al., Therapeutic drug monitoring of beta-lactam antibiotics in burns patients-a one-year prospective study. Ther Drug Monit. 2012; 34 (2): 160-164. doi: 10.1097/FTD.0b013e31824981a6.
7. Scaglione F, Esposito S, Leone S, et al., Feedback dose alteration significantly affects probability of pathogen eradication in nosocomial pneumonia. Eur Respir J. 2009; 34 (2): 394-400. doi: 10.1183/09031936.00149508.
8. De Waele JJ, Carrette S, Carlier M, et al., Therapeutic drug monitoring-based dose optimisation of piperacillin and meropenem: a randomised controlled trial. Intensive Care Med. 2014; 40 (3): 380-387. doi: 10.1007/s00134-013-3187-2.
9. Taccone FS, Cotton F, Roisin S, Vincent J-L, Jacobs F., Optimal meropenem concentrations to treat multidrug-resistant Pseudomonas aeruginosa septic shock. Antimicrob Agents Chemother. 2012; 56 (4): 2129-2131. doi: 10.1128/AAC.06389-11.
10. Pea F, Cojutti, P, Sbrojavacca, R, et al., TDM-guided therapy with daptomycin and meropenem in a morbidly obese, critically ill patient. Ann Pharmacother. 2011; 45 (7-8): e37-e37. doi: 10.1345/aph.1P745.
11. Sime FB, Roberts MS, Peake SL, Lipman J, Roberts JA,. Does beta-lactam pharmacokinetic variability in critically ill patients justify therapeutic drug monitoring? A systematic review. Ann Intensive Care. 2012; 2 (1): 35. doi: 10.1186/2110-5820-2-35.
12. Wong G, Brinkman A, Benefield RJ, et al., An international, multicentre survey of β-lactam antibiotic therapeutic drug monitoring practice in intensive care units. J Antimicrob Chemother. 2014; 69 (5): 1416-1423.
13. Mouton JW, van den Anker JN,. Meropenem clinical pharmacokinetics. Clin Pharmacokinet. 1995; 28 (4): 275-286. doi: 10.2165/00003088-199528040-00002.
14. Cockcroft DW, Gault MH,. Prediction of creatinine clearance from serum creatinine. Nephron. 1976; 16 (1): 31-41.
15. Martin C, Alaya M, Bras J, Saux P, Gouin F,. Assessment of creatinine clearance in intensive care patients. Crit Care Med. 1990; 18 (11): 1224-1226.
16. Hoste EAJ, Damen J, Vanholder RC, et al., Assessment of renal function in recently admitted critically ill patients with normal serum creatinine. Nephrol Dial Transpl. 2005; 20 (4): 747-753. doi: 10.1093/ndt/gfh707.
17. Bunnan LA, Nilsson-Ehle I, Hutchison M, Haworth SJ, Norrby SR,. Pharmacokinetics of meropenem and its metabolite ICI 213,689 in healthy subjects with known renal metabolism of imipenem. J Antimicrob Chemother. 1991; 27 (2): 219-224.
18. Christensson BA, Nilsson-Ehle I, Hutchison M, Haworth SJ, Oqvist B, Norrby SR,. Pharmacokinetics of meropenem in subjects with various degrees of renal impairment. Antimicrob Agents Chemother. 1992; 36 (7): 1532-1537.
19. Ljungberg B, Nilsson-Ehle I,. Pharmacokinetics of meropenem and its metabolite in young and elderly healthy men. Antimicrob Agents Chemother. 1992; 36 (7): 1437-1440. doi: 10.1128/AAC.36.7.1437.
20. Chimata M, Nagase M, Suzuki Y, Shimomura M, Kakuta S,. Pharmacokinetics of meropenem in patients with various degrees of renal function, including patients with end-stage renal disease. Antimicrob Agents Chemother. 1993; 37 (2): 229-233.
21. McWhinney BC, Wallis SC, Hillister T, Roberts JA, Lipman J, Ungerer JPJ. Analysis of 12 beta-lactam antibiotics in human plasma by HPLC with ultraviolet detection. J Chromatogr B. 2010; 878 (22): 2039-2043. doi: 10.1016/j.jchromb.2010.05.027.
22. Craig WA,. The pharmacology of meropenem, a new carbapenem antibiotic. Clin Infect Dis. 1997; 24 (Suppl 2): S266-S275. doi: 10.1093/clinids/24.Supplement-2.S266.
23. Grubb A, Blirup-Jensen S, Lindström V, Schmidt C, Althaus H, Zegers I,. First certified reference material for cystatin C in human serum ERM-DA471/IFCC. Clin Chem Lab Med. 2010; 48 (11): 1619-1621.
24. Dubois D, Dubois EF,. A formula to estimate the approximate surface area if height and weight be known. Arch Intern Med. 1916; 17: 863-871.
25. Hoek FJ, Kemperman FAW, Krediet RT,. A comparison between cystatin C, plasma creatinine and the Cockcroft and Gault formula for the estimation of glomerular filtration rate. Nephrol Dial Transpl. 2003; 18 (10): 2024-2031. doi: 10.1093/ndt/gfg349.
26. Keizer RJ, Karlsson MO, Hooker A,. Modeling and simulation workbench for NONMEM: tutorial on pirana, PsN, and Xpose. CPT Pharmacomet Syst Pharmacol. 2013; 2 (6): e50. doi: 10.1038/psp.2013.24.
27. Mouton JW, Michel MF,. Pharmacokinetics of meropenem in serum and suction blister fluid during continuous and intermittent infusion. J Antimicrob Chemother. 1991; 28 (6): 911-918.
28. Krueger WA, Bulitta J, Kinzig-Schippers M, et al. Evaluation by Monte Carlo simulation of the pharmacokinetics of two doses of meropenem administered intermittently or as a continuous infusion in healthy volunteers. Antimicrob Agents Chemother. 2005; 49 (5): 1881-1889. doi: 10.1128/AAC.49.5.1881-1889.2005.
29. Thalhammer F, Traunmüller F, Menyawi IE, et al. Continuous infusion versus intermittent administration of meropenem in critically ill patients. J Antimicrob Chemother. 1999; 43 (4): 523-527. doi: 10.1093/jac/43.4.523.
30. Roberts JA, Kirkpatrick CMJ, Roberts MS, Robertson TA, Dalley AJ, Lipman J,. Meropenem dosing in critically ill patients with sepsis and without renal dysfunction: intermittent bolus versus continuous administration? Monte Carlo dosing simulations and subcutaneous tissue distribution. J Antimicrob Chemother. 2009; 64 (1): 142-150. doi: 10.1093/jac/dkp139.
31. Langgartner J, Vasold A, Glück T, Reng M, Kees F,. Pharmacokinetics of meropenem during intermittent and continuous intravenous application in patients treated by continuous renal replacement therapy. Intensive Care Med. 2008; 34 (6): 1091-1096. doi: 10.1007/s00134-008-1034-7.
32. Bax RP, Bastain W, Featherstone A, Wilkinson DM, Hutchison M, Haworth SJ,. The pharmacokinetics of meropenem in volunteers. J Antimicrob Chemother. 1989; 24 (Suppl A): 311-320.
33. Kropp H, Sundelof JG, Hajdu R, Kahan FM,. Metabolism of thienamycin and related carbapenem antibiotics by the renal dipeptidase, dehydropeptidase. Antimicrob Agents Chemother. 1982; 22 (1): 62-70.
34. Kees MG, Hilpert JW, Gnewuch C, Kees F, Voegeler S,. Clearance of vancomycin during continuous infusion in intensive care unit patients: correlation with measured and estimated creatinine clearance and serum cystatin C. Int J Antimicrob Agents. 2010; 36 (6): 545-548. doi: 10.1016/j.ijantimicag.2010.07.015.
35. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D,. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med. 1999; 130 (6): 461-470.
36. Levey AS, Stevens LA, Schmid CH, et al., A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009; 150 (9): 604-612.
37. Baptista JP, Neves M, Rodrigues L, Teixeira L, Pinho J, Pimentel J,. Accuracy of the estimation of glomerular filtration rate within a population of critically ill patients. J Nephrol. 2014; 27 (4): 403-410.
38. Pea F, Viale P, Cojutti P, Furlanut M,. Dosing nomograms for attaining optimum concentrations of meropenem by continuous infusion in critically ill patients with severe Gram-negative infections: a pharmacokinetics/pharmacodynamics-based approach. Antimicrob Agents Chemother. 2012; 56 (12): 6343-6348. doi: 10.1128/AAC.01291-12.